Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NERV 
Minerva Neurosciences Inc (NERV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NERV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.13% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.64M USD | Price to earnings Ratio 1.61 | 1Y Target Price 5 |
Price to earnings Ratio 1.61 | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta -0.34 | 52 Weeks Range 1.15 - 3.00 | Updated Date 08/29/2025 |
52 Weeks Range 1.15 - 3.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.48 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.9 | Actual -0.43 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.34% | Return on Equity (TTM) -675.09% |
Valuation
Trailing PE 1.61 | Forward PE 11.21 | Enterprise Value 1396396 | Price to Sales(TTM) 1.87 |
Enterprise Value 1396396 | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 0.12 | Shares Outstanding 6993410 | Shares Floating 5437023 |
Shares Outstanding 6993410 | Shares Floating 5437023 | ||
Percent Insiders 22.25 | Percent Institutions 27.99 |
Upturn AI SWOT
Minerva Neurosciences Inc
Company Overview
History and Background
Minerva Neurosciences Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) diseases. Founded in 2007, it has primarily focused on developing novel drug candidates for unmet needs in psychiatry.
Core Business Areas
- Clinical Development: Focuses on advancing drug candidates through clinical trials to seek regulatory approval.
- Research and Discovery: Identifies and evaluates new potential drug candidates and therapeutic targets within the CNS space.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure is typical of a biotech company, with departments focused on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Rolerperidone: Rolerperidone is Minerva's most advanced product candidate, in development for the treatment of negative symptoms of schizophrenia. No significant market share to date as not yet approved. Competitors include pharmaceutical companies with approved schizophrenia treatments, such as Janssen (INVEGA), Otsuka (ABILIFY), and Alkermes (ARISTADA).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in CNS disorders, is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. There is a significant unmet need for new and effective treatments for schizophrenia and other mental health disorders.
Positioning
Minerva is positioned as a company focused on developing innovative therapies for underserved patient populations within the CNS space. Success depends on the approval and commercialization of Rolerperidone or other future candidates.
Total Addressable Market (TAM)
The total addressable market for schizophrenia treatments is estimated to be in the billions of dollars annually. Minerva, if Rolerperidone is approved, is aiming to capture a share of this market, particularly within the negative symptom subsegment.
Upturn SWOT Analysis
Strengths
- Focused pipeline on addressing unmet medical needs in CNS disorders
- Innovative drug candidates with potential for improved efficacy and safety profiles
- Experienced management team
Weaknesses
- Reliance on the success of Rolerperidone
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
Opportunities
- Potential for FDA approval and commercialization of Rolerperidone
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion of the pipeline through in-licensing or acquisition of new drug candidates
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from existing and emerging therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- LLY
Competitive Landscape
Minerva faces intense competition from established pharmaceutical companies with approved treatments for schizophrenia. Its advantage lies in potentially offering a novel treatment specifically targeting negative symptoms.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the advancement of Rolerperidone through clinical trials.
Future Projections: Future growth is contingent on the successful development and commercialization of Rolerperidone and other pipeline candidates. Analyst projections are speculative and depend heavily on regulatory outcomes.
Recent Initiatives: Recent initiatives include advancing Rolerperidone through regulatory review processes.
Summary
Minerva Neurosciences is a high-risk, high-reward biopharmaceutical company focused on CNS disorders. Its success hinges on the approval and commercialization of Rolerperidone. The company's financial resources are limited, and it faces significant competition. Regulatory approval is crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on available information and is not financial advice. Investing in biotech companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Minerva Neurosciences Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2014-07-01 | Executive Chairman & CEO Dr. Remy Luthringer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | |
Full time employees 8 | |||
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.